ELIGARD® (leuprolide acetate for injectable suspension)

ELIGARD is indicated for the palliative treatment of advanced prostate cancer. ELIGARD is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver leuprolide acetate at a controlled rate over a 1-, 3-, 4-, or 6-month therapeutic period. ELIGARD is the only LHRH agonist with the innovative controlled-release ATRIGEL® Delivery System. ELIGARD is marketed in 4 single-dosage strengths:

  • ELIGARD 7.5 mg: 1 month of therapy
  • ELIGARD 22.5 mg: 3 months of therapy
ELIGARD 30 mg: 4 months of therapy
ELIGARD 45 mg: 6 months of therapy

ELIGARD is a global product, marketed in over 67 countries. ELIGARD is marketed in the U.S., Australia, and New Zealand by TOLMAR, and by the following partners in the remaining territories:

  • Astellas (Europe, Asia, and MENA)
  • Sanofi (Canada)
  • Key Oncologics (South Africa)
  • HanAll (South Korea)